Brief: Nymox Reports 5-Yr Results From Prostate Cancer Study Of Fexapotide Triflutate In 146 U.S. Men
22/01/2018 16:30
Jan 22 (Reuters) - Nymox Pharmaceutical Corp NYMX.O :
* NYMOX REPORTS 5-YEAR RESULTS FROM PROSPECTIVE RANDOMIZED
CONTROLLED PROSTATE CANCER STUDY OF FEXAPOTIDE TRIFLUTATE IN 146
U.S. MEN
* NYMOX - HIGH DOSE FEXAPOTIDE 15MG SINGLE DOSAGE TREATMENT
RESULTED IN 80% LESS SURGERY OR RADIOTHERAPY ASSOCIATED WITH
GLEASON GRADE PROGRESSION
* NYMOX PHARMACEUTICAL CORP - STUDY ALSO SHOWED THAT BOTH
DOSES OF
FEXAPOTIDE WERE CONSISTENTLY EFFECTIVE
Source text for Eikon: ID:nGNXOMNBAa
Further company coverage: NYMX.O
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Nymox Pharmaceutical
See all newsBrief: Nymox Says Required To Resubmit Application To DKMA
Brief: Nymox Pharmaceutical Corp Says Terminated Employment Of Christopher R Riley As CFO (June 27)
Brief: Nymox Announces Appointment Of Christopher R. Riley As Chief Financial Officer
Brief: Nymox Appeals Deficiency Letter
U.S. STOCKS ON THE MOVE-Pot stocks, Nymox, Zynerba